PDCD1 and neoplasm: The rationale is, in addition to targeting the GPNMB+ cells with the antibody-coupled to the toxin, the anti-PD-1 antibodies suppress the tumor-promoted inhibition of the antitumor immune response, while the anti-CD27 triggers an activation of the cytotoxic T lymphocytes (CTL).